JP Patent

JP7444957B2 — ２－ヒドロキシ－６－（（２－（１－イソプロピル－１ｈ－ピラゾール－５－イル）ピリジン－３－イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形

Assigned to グローバル ブラッド セラピューティクス インコーポレイテッド · Expires 2024-03-06 · 2y expired

What this patent protects

Patent listed against Oxbryta.

Drugs covered by this patent

Patent Metadata

Patent number
JP7444957B2
Jurisdiction
JP
Classification
—
Expires
2024-03-06
Drug substance claim
No
Drug product claim
No
Assignee
グローバル ブラッド セラピューティクス インコーポレイテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.